This excerpt taken from the NVS 6-K filed Oct 9, 2008.
Early data show potential for imatinib to treat life-threatening form of pulmonary artery disease
· Exploratory study shows clinical improvement in patients with pulmonary arterial hypertension (PAH)
· Current treatment options have limited benefit for this debilitating, rapidly progressive and incurable blood vessel disease
· Imatinib, available as Glivec® for treatment of certain cancers, known to inhibit protein associated with PAH
· Novartis to further explore potential of imatinib in PAH in 2009